Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure

EVLIN L. KINNEY, BRIAN CARLIN, JAMES O. BALLARD, JOHN M. BURKS, WILLIAM F. HALLAHAN, ROBERT ZELIS

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Abstract: To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded. 1982 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)433-440
Number of pages8
JournalThe Journal of Clinical Pharmacology
Volume22
Issue number10
DOIs
StatePublished - Oct 1982

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure'. Together they form a unique fingerprint.

Cite this